
  
    
      
        Background_NNP
        
          Antigenic_NNP drift_VB and_CC the_DT generation_NN of_IN viral_JJ
          quasispecies_NNS
          Some_DT RNA_NNP viruses_NNS form_VBP a_DT quasispecies--a_JJ set_NN of_IN related_VBN
          viral_JJ variants_NNS that_WDT coexist_NN in_IN field_NN populations_NNS and_CC even_RB
          within_IN single_JJ infected_JJ individuals_NNS (_( reviewed_VBN in_IN [_NN 1_CD ,_, 2_CD ,_,
          3_CD ,_, 4_CD ,_, 5_CD ]_NN )_) ._. The_DT emergence_NN of_IN immunologically_RB distinct_JJ
          members_NNS of_IN a_DT viral_JJ quasispecies_NNS through_IN mutation_NN and_CC
          subsequent_JJ immune_JJ selection_NN is_VBZ called_VBN "_'' antigenic_JJ drift_NN ._. "_''
          Antigenic_NNP drift_VB is_VBZ thought_VBN to_TO be_VB important_JJ in_IN human_JJ
          immunodeficiency_NN virus_NN (_( HIV_NNP )_) infection_NN and_CC the_DT continuing_VBG
          seasonal_JJ influenza_NN epidemics_NNS because_IN immunity_NN generated_VBN
          against_IN one_CD viral_JJ quasispecies_NNS member_NN selects_VBZ for_IN escape_NN
          variants_NNS ._. Attributed_NNP in_IN part_NN to_TO antigenic_JJ drift_NN are_VBP the_DT
          moderately_RB high_JJ failure_NN rate_NN and_CC the_DT short-lived_JJ efficacy_NN
          of_IN influenza_NN vaccines_NNS [_NN 6_CD ]_NN ,_, the_DT failure_NN of_IN synthetic_JJ
          foot-and-mouth_JJ disease_NN virus_NN vaccines_NNS [_NN 7_CD ]_NN ,_, and_CC the_DT
          inability_NN of_IN recombinant_JJ HIV_NNP vaccines_NNS to_TO provide_VB complete_JJ
          protection_NN against_IN field_NN strains_NNS of_IN the_DT virus_NN [_NN 8_CD ]_NN ._.
          The_DT hemagglutinin_NN (_( HA_NNP )_) envelope_NN surface_NN
          glycoprotein--the_JJ major_JJ neutralizing_VBG determinant_NN of_IN
          influenza_NN A--_NNP is_VBZ a_DT classic_JJ example_NN of_IN an_DT antigenically_RB
          drifting_VBG protein_NN [_NN 9_CD ]_NN ._. Walter_NNP Gerhard_NNP and_CC colleagues_NNS
          demonstrated_VBN that_IN the_DT immune_JJ pressure_NN exerted_VBN by_IN
          monoclonal_NN antibodies_NNS (_( Abs_NNP )_) selects_VBZ for_IN HA_NNP escape_VB mutants_NNS
          in_IN model_NN systems_NNS [_NN 10_CD ,_, 11_CD ]_NN ._. Later_RB ,_, Dimmock_NNP and_CC colleagues_NNS
          showed_VBD that_DT polyclonal_NN anti-sera_JJ also_RB select_VB for_IN escape_NN
          mutants_NNS [_NN 12_CD ,_, 13_CD ]_NN ._. Similarly_RB ,_, much_JJ of_IN the_DT observed_VBN
          variability_NN of_IN glycoprotein_NN 120_CD (_( gp_NN 120_CD )_) ,_, the_DT principal_JJ
          surface_NN antigen_NN of_IN HIV_NNP ,_, is_VBZ thought_VBN to_TO reflect_VB antigenic_JJ
          drift_NN [_NN 14_CD ,_, 15_CD ,_, 16_CD ,_, 17_CD ]_NN ._. The_DT correlation_NN of_IN intra-patient_JJ
          viral_JJ diversity_NN with_IN immune_JJ response_NN strength_NN has_VBZ been_VBN
          cited_VBN as_IN evidence_NN that_IN the_DT immune_JJ response_NN is_VBZ a_DT selective_JJ
          factor_NN in_IN HIV_NNP antigenic_JJ drift_NN [_NN 18_CD ,_, 19_CD ,_, 20_CD ,_, 21_CD ,_, 22_CD ]_NN ._.
          Phylogenetic_NNP analyses_NNS describe_VBP divergence_NN within_IN a_DT
          viral_JJ population_NN ,_, and_CC these_DT methods_NNS have_VBP been_VBN used_VBN to_TO
          infer_NN the_DT selective_JJ advantages_NNS of_IN viral_JJ variation_NN [_NN 18_CD ,_,
          19_CD ,_, 20_CD ,_, 21_CD ,_, 22_CD ,_, 23_CD ,_, 24_CD ,_, 25_CD ,_, 26_CD ,_, 27_CD ,_, 28_CD ,_, 29_CD ,_, 30_CD ]_NN ._. A_DT more_RBR
          direct_JJ indication_NN of_IN the_DT selective_JJ advantage_NN gained_VBD
          through_IN variation_NN is_VBZ an_DT observed_VBN overabundance_NN of_IN
          replacement_NN mutations_NNS relative_JJ to_TO silent_JJ mutations_NNS in_IN
          viral_JJ proteins_NNS [_NN 31_CD ]_NN ._. Such_JJ analyses_NNS of_IN gp_NN 120_CD and_CC its_PRP$ V_NNP
          regions_NNS indicate_VBP that_IN replacement_NN mutations_NNS are_VBP generally_RB
          over-represented_JJ in_IN this_DT protein_NN and_CC thus_RB appear_VB to_TO
          confer_VB selective_JJ advantage_NN to_TO HIV-_NNP 1_CD [_NN 22_CD ,_, 24_CD ,_, 25_CD ,_, 26_CD ,_, 27_CD ,_,
          28_CD ,_, 29_CD ,_, 30_CD ,_, 32_CD ,_, 33_CD ,_, 34_CD ,_, 35_CD ]_NN ._. In_IN more_RBR detailed_JJ analyses_NNS ,_,
          several_JJ groups_NNS tested_VBD individual_JJ codons_NNS for_IN replacement_NN
          mutations_NNS that_WDT are_VBP ,_, as_IN an_DT aggregate_NN ,_, overabundant_NN [_NN 23_CD ,_,
          36_CD ,_, 37_CD ,_, 38_CD ]_NN ._. However_RB ,_, none_NN of_IN these_DT methods_NNS determine_VBP
          which_WDT replacement_NN mutations_NNS are_VBP actually_RB positively_RB
          selected_VBN ._. Also_RB ,_, when_WRB replacement_NN mutations_NNS of_IN varying_VBG
          fitness_NN are_VBP lumped_VBN together_RB ,_, positively_RB selected_VBN
          mutations_NNS may_MD remain_VB undetected_JJ among_IN negatively_RB selected_VBN
          mutations_NNS ._.
          To_TO overcome_VB these_DT limitations_NNS ,_, we_PRP have_VBP developed_VBN a_DT
          "_'' selection_NN mapping_NN "_'' algorithm_NN ._. The_DT cornerstone_NN of_IN
          selection_NN mapping_NN is_VBZ the_DT testing_NN of_IN each_DT observed_VBN
          replacement_NN mutation_NN at_IN each_DT codon_NN to_TO identify_VB those_DT
          particular_JJ replacement_NN mutations_NNS that_WDT are_VBP overabundant_NN
          relative_JJ to_TO silent_JJ mutations_NNS at_IN that_DT codon_NN ._. Such_JJ
          replacement_NN mutations_NNS are_VBP determined_VBN to_TO be_VB positively_RB
          selected_VBN ._. Negatively_NNP selected_VBD variants_NNS are_VBP recognized_VBN as_IN
          "_'' noise_NN "_'' and_CC are_VBP thereafter_RB ignored_VBN ._. Here_RB ,_, we_PRP use_VBP the_DT
          selection_NN mapping_NN method_NN to_TO identify_VB the_DT positively_RB
          selected_VBN variants_NNS of_IN influenza_NN A_DT HA_NNP (_( H_NNP 3_CD serotype_NN )_) ,_, HIV-_NNP 1_CD
          reverse_VB transcriptase_NN (_( RT_NNP )_) ,_, and_CC HIV-_NNP 1_CD gp_NN 120_CD ._.
        
      
      
        Results_NNS and_CC Discussion_NNP
        
          Selection_NN map_NN of_IN influenza_NN A_DT H_NNP 3_CD
          hemagglutinin_NN
          QUASI_NNP identifies_VBZ 25_CD HA_NNP codons_NNS where_WRB one_CD or_CC more_JJR
          replacement_NN mutations_NNS are_VBP positively_RB selected_VBN in_IN the_DT
          influenza_NN A_DT H_NNP 3_CD virus_NN (_( Fig_NNP ._. 1_LS )_) ._. [_NN From_IN our_PRP$ neutral_JJ drift_NN
          testing_NN of_IN QUASI_NNP ,_, we_PRP expect_VBP a_DT maximum_NN of_IN about_IN 2_CD -_: 3_CD false_JJ
          positives_NNS (_( see_VB Materials_NNPS and_CC Methods_NNP )_) ]_NN ._. The_DT distribution_NN
          of_IN these_DT positively_RB selected_VBN codons_NNS is_VBZ of_IN particular_JJ
          interest_NN ._. Without_IN exception_NN ,_, the_DT codons_NNS where_WRB variants_NNS
          are_VBP positively_RB selected_VBN are_VBP on_IN the_DT HA_NNP surface_NN (_( Fig_NNP ._. 2_LS ,_,
          left_VBD )_) ._. The_DT parsimonious_JJ explanation_NN of_IN this_DT result_NN is_VBZ
          that_IN HA_NNP variants_NNS are_VBP primarily_RB selected_VBN for_IN escape_NN from_IN
          B-_NNP cell_NN immunity_NN ._. If_IN T-_NNP cell_NN immunity_NN is_VBZ instead_RB the_DT
          primary_JJ selective_JJ force_NN affecting_VBG HA_NNP variation_NN ,_, then_RB
          either_CC all_DT T-_NNP cell_NN immunity_NN escape_NN variants_NNS are_VBP
          coincidentally_RB solvent-exposed_JJ ,_, or_CC HA_NNP T-_NNP cell_NN epitopes_NNS are_VBP
          determined_VBN by_IN Ab_NNP protection_NN [_NN 39_CD ]_NN ._. These_DT 25_CD codons_NNS
          include_VBP 13_CD outside_IN those_DT identified_VBN as_RB positively_RB
          selected_VBN by_IN Walter_NNP Fitch_NNP and_CC colleagues_NNS [_NN 40_CD ]_NN ._. We_PRP
          attribute_VBP our_PRP$ new_JJ findings_NNS primarily_RB to_TO sites_NNS where_WRB many_JJ
          variants_NNS are_VBP negatively_RB selected_VBN but_CC where_WRB at_IN least_JJS one_CD
          variant_NN is_VBZ positively_RB selected_VBN ._. The_DT Fitch_NNP group_NN also_RB
          identifies_VBZ 6_CD additional_JJ codons_NNS as_RB positively_RB selected_VBN ._. We_PRP
          believe_VBP that_IN these_DT are_VBP false_JJ positives_NNS caused_VBN by_IN the_DT
          Fitch_NNP group_NN 's_POS assumption_NN that_IN HA_NNP is_VBZ ,_, on_IN average_JJ ,_,
          neutrally_RB drifting_VBG ;_: these_DT six_CD codons_NNS may_MD be_VB less_RBR
          negatively_RB selected_VBN than_IN average_JJ ,_, but_CC they_PRP nevertheless_RB
          appear_VBP to_TO be_VB negatively_RB selected_VBN ._. Additionally_RB ,_, our_PRP$ data_NNS ,_,
          while_IN largely_RB the_DT same_JJ as_IN those_DT analyzed_VBN by_IN the_DT Fitch_NNP
          group_NN ,_, do_VBP have_VBP some_DT differences_NNS ._.
          Wiley_NNP 
          et_CC al_NN ._. proposed_VBN four_CD antigenic_JJ
          sites_NNS where_WRB field_NN and_CC laboratory_NN mutations_NNS could_MD be_VB
          grouped_VBN on_IN the_DT HA_NNP surface_NN [_NN 41_CD ]_NN ._. These_DT putative_JJ antigenic_JJ
          sites_NNS are_VBP indicated_VBN in_IN Figure_NN 1_CD and_CC the_DT right_JJ side_NN of_IN
          Figure_NN 2_CD ._. Positively_NNP selected_VBD variants_NNS are_VBP correlated_JJ
          (_( Fisher_NNP 's_POS exact_JJ test_NN )_) with_IN antigenic_JJ site_NN A_DT (_( p_NN =_SYM 5_CD ._. 27_CD ×_NN
          10_CD -_: 3_LS )_) ,_, antigenic_JJ site_NN B_NNP (_( p_NN =_SYM 1_CD ._. 12_CD ×_NN 10_CD -_: 3_LS )_) ,_, and_CC
          antigenic_JJ site_NN C_NNP (_( p_NN =_SYM 1_CD ._. 0_CD ×_NN 10_CD -_: 5_LS )_) ._. In_IN contrast_NN ,_,
          antigenic_JJ site_NN D_NNP is_VBZ not_RB particularly_RB correlated_JJ with_IN
          positively_RB selected_VBN variants_NNS ._. We_PRP believe_VBP the_DT lack_NN of_IN
          positively_RB selected_VBN variants_NNS spanning_VBG antigenic_JJ site_NN D_NNP
          may_MD explain_VB a_DT decades-old_JJ puzzle_NN ._. In_IN the_DT fully_RB assembled_VBN
          HA_NNP protein_NN ,_, site_NN D_NNP is_VBZ buried_VBN in_IN the_DT trimer_NN interface_NN and_CC
          therefore_RB is_VBZ not_RB generally_RB accessible_JJ to_TO Ab_NNP [_NN 41_CD ,_, 42_CD ]_NN ._. At_IN
          the_DT time_NN that_IN the_DT antigenic_JJ sites_NNS were_VBD proposed_VBN ,_, residues_NNS
          in_IN and_CC around_IN the_DT trimer_NN interface_NN were_VBD variable_JJ and_CC
          found_VBD on_IN the_DT monomer_NN surface_NN ,_, so_IN they_PRP were_VBD grouped_VBN and_CC
          labeled_VBN as_IN antigenic_JJ site_NN D_NNP even_RB though_IN it_PRP was_VBD unclear_JJ
          how_WRB site_NN D_NNP was_VBD recognized_VBN by_IN Ab_NNP [_NN 41_CD ]_NN ._. In_IN fact_NN ,_, the_DT only_RB
          two_CD positively_RB selected_VBN variants_NNS QUASI_NNP identifies_VBZ in_IN site_NN
          D_NNP are_VBP solvent-exposed_JJ at_IN the_DT extreme_JJ edge_NN of_IN the_DT HA_NNP
          trimer_NN (_( Fig_NNP ._. 2_LS )_) ._. Based_VBN on_IN QUASI_NNP 's_POS selection_NN map_NN of_IN HA_NNP ,_, we_PRP
          now_RB conclude_VBP that_IN those_DT mutations_NNS found_VBD in_IN the_DT
          trimer-buried_JJ portion_NN of_IN HA_NNP do_VBP not_RB confer_VB significant_JJ
          advantage_NN on_IN influenza_NN A_DT ._. That_DT is_VBZ ,_, while_IN the_DT
          trimer-buried_JJ portion_NN of_IN antigenic_JJ site_NN D_NNP includes_VBZ the_DT
          sound_NN and_CC fury_NN of_IN variability_NN ,_, it_PRP signifies_NNS nothing_NN ._.
          While_IN QUASI_NNP finds_VBZ that_IN antigenic_JJ sites_NNS A-C_NNP are_VBP
          significantly_RB associated_VBN with_IN positively_RB selected_VBN
          variation_NN ,_, this_DT association_NN may_MD be_VB a_DT simple_JJ consequence_NN
          of_IN the_DT sites_NNS '_POS surface_NN exposure_NN ._. As_IN can_MD be_VB seen_VBN in_IN the_DT
          left-hand_JJ side_NN of_IN Figure_NN 2_CD ,_, positively_RB selected_VBN variants_NNS
          are_VBP scattered_VBN across_IN the_DT entire_JJ exposed_VBN surface_NN of_IN HA_NNP ._.
          There_EX are_VBP positively_RB selected_VBN variants_NNS outside_IN the_DT
          antigenic_JJ sites_NNS ,_, and_CC there_EX are_VBP subregions_NNS of_IN the_DT
          antigenic_JJ sites_NNS where_WRB variation_NN is_VBZ negatively_RB selected_VBN ._.
          Thus_RB ,_, it_PRP may_MD be_VB more_RBR appropriate_JJ to_TO view_VB antigenic_JJ sites_NNS
          as_IN more_RBR positional_JJ than_IN functional_JJ ._. Indeed_RB ,_, more_RBR recent_JJ
          demarcations_NNS of_IN antigenic_JJ sites_NNS enlarge_VB antigenic_JJ sites_NNS
          A-D_NNP and_CC add_VB an_DT additional_JJ antigenic_JJ site_NN ,_, site_NN E_NNP ,_, and_CC
          these_DT sites_NNS are_VBP now_RB considered_VBN primarily_RB positional_JJ
          rather_RB than_IN functional_JJ [_NN 6_CD ,_, 43_CD ]_NN ._.
        
        
          Selection_NN map_NN of_IN HIV-_NNP 1_CD gp_NN 120_CD
          At_IN 123_CD codons_NNS ,_, QUASI_NNP 's_POS selection_NN map_NN of_IN gp_NN 120_CD
          indicates_VBZ that_IN one_CD or_CC more_RBR non-consensus_JJ amino_JJ acids_NNS are_VBP
          positively_RB selected_VBN in_IN HIV-_NNP 1_CD (_( Fig_NNP ._. 3_LS )_) ._. Most_JJS positively_RB
          selected_VBN variants_NNS appear_VBP to_TO be_VB on_IN the_DT gp_NN 120_CD surface_NN (_( not_RB
          shown_VBN )_) ,_, but_CC in_IN contrast_NN to_TO HA_NNP ,_, gp_NN 120_CD includes_VBZ several_JJ
          monomer-buried_JJ positively_RB selected_VBN variants_NNS (_( at_IN sites_NNS
          I_PRP 225_CD ,_, V_NNP 270_CD ,_, N_NNP 295_CD ,_, H_NNP 333_CD ,_, I_PRP 345_CD ,_, T_NN 387_CD ,_, I_PRP 424_CD ,_, and_CC L_NNP 453_CD )_) ._.
          Additionally_RB ,_, some_DT of_IN the_DT positively_RB selected_VBN variants_NNS
          that_WDT appear_VBP to_TO be_VB solvent-exposed_JJ may_MD normally_RB be_VB buried_VBN
          (_( some_DT loops_NNS are_VBP absent_JJ from_IN the_DT core_NN protein_NN crystal_NN
          structure_NN [_NN 44_CD ]_NN )_) ._. The_DT burial_NN of_IN positively_RB selected_VBN
          variants_NNS in_IN the_DT gp_NN 120_CD monomer_NN confirms_VBZ that_DT gp_NN 120_CD
          quasispeciation_NN is_VBZ not_RB selected_VBN solely_RB for_IN escape_NN from_IN
          B-_NNP cell_NN immunity_NN ._.
          Two_CD competition-group_JJ epitopes_NNS have_VBP been_VBN identified_VBN
          for_IN broadly_RB neutralizing_VBG anti-gp_JJ 120_CD Abs_NNP :_: the_DT CD_NNP 4_CD -_: binding_JJ
          site_NN (_( CD_NNP 4_CD BS_NNP )_) and_CC the_DT CD_NNP 4_CD -_: induced_VBN (_( CD_NNP 4_CD i_NNP )_) epitopes_NNS
          (_( references_NNS in_IN [_NN 45_CD ]_NN )_) ._. Each_DT epitope_NN includes_VBZ only_RB a_DT
          single_JJ non-consensus_JJ positively_RB selected_VBN variant_NN (_( Fig_NNP ._.
          3_LS )_) ._. Thus_RB ,_, broadly_RB neutralizing_VBG Abs_NNP appear_VBP to_TO be_VB those_DT
          that_WDT engage_VBP few_JJ protein_NN positions_NNS where_WRB variation_NN is_VBZ
          positively_RB selected_VBN ._. Based_VBN on_IN this_DT observation_NN ,_, we_PRP
          propose_VBP that_IN the_DT neutralizing_VBG spectra_NN of_IN Abs_NNP may_MD be_VB
          predicted_VBN if_IN the_DT epitopes_NNS are_VBP known_VBN ._. For_IN example_NN ,_, we_PRP
          would_MD predict_VB that_IN the_DT anti-_NN CD_NNP 4_CD BS_NNP Abs_NNP will_MD have_VB
          particular_JJ trouble_NN recognizing_VBG gp_NN 120_CD molecules_NNS carrying_VBG
          the_DT positively_RB selected_VBN variant_NN of_IN the_DT CD_NNP 4_CD BS_NNP epitope_NN (_( D_NNP →_NN N_NNP
          at_IN codon_NN 474_CD )_) ._. This_DT prediction_NN is_VBZ fulfilled_VBN in_IN that_IN the_DT
          15_CD e_SYM anti-_NN CD_NNP 4_CD BS_NNP monoclonal_NN Ab_NNP fails_VBZ to_TO react_VB to_TO gp_NN 120_CD from_IN
          HIV_NNP strain_NN RF_NNP ,_, a_DT strain_NN that_WDT carries_VBZ this_DT D_NNP →_NN N_NNP mutation_NN [_NN
          46_CD ]_NN ._. We_PRP also_RB predict_VBP that_DT gp_NN 120_CD molecules_NNS carrying_VBG the_DT
          positively_RB selected_VBN I_PRP →_NN F_NN mutation_NN at_IN codon_NN 423_CD will_MD be_VB
          poorly_RB recognized_VBN by_IN the_DT anti-_NN CD_NNP 4_CD i_NNP Abs_NNP ._.
          It_PRP is_VBZ worth_JJ commenting_VBG on_IN the_DT GPGRAF_NNP motif_NN (_( gp_NN 120_CD
          residues_NNS 312_CD -_: 317_CD )_) that_WDT is_VBZ sometimes_RB (_( though_IN increasingly_RB
          rarely_RB )_) referred_VBD to_TO as_IN "_'' highly_RB conserved_JJ ._. "_'' Because_IN QUASI_NNP
          identifies_VBZ non-consensus_JJ variants_NNS at_IN two_CD codons_NNS of_IN this_DT
          motif_NN as_RB positively_RB selected_VBN (_( Fig_NNP ._. 3_LS )_) ,_, it_PRP may_MD be_VB
          inappropriate_JJ to_TO refer_VB to_TO the_DT GPGRAF_NNP motif_NN as_IN "_'' highly_RB
          conserved_JJ ._. "_'' Instead_RB ,_, five_CD positively_RB selected_VBN variants_NNS
          appear_VBP to_TO exist_VB at_IN this_DT region_NN in_IN addition_NN to_TO GPGRAF_NNP :_:
          GPGKAF_NNP ,_, GPGRTF_NNP ,_, GPGKTF_NNP ,_, GPGRVF_NNP ,_, and_CC GPGKVF_NNP ._.
          Kwong_NNP 
          et_CC al_NN ._. roughly_RB divide_VBP the_DT gp_NN 120_CD
          three-dimensional_JJ structure_NN into_IN outer_JJ (_( β_NN 9_CD -_: β_NN 19_CD and_CC
          β_NN 22_CD -_: β_NN 24_CD )_) and_CC inner_JJ (_( N-_NNP α_NN 1_CD ,_, β_NN 4_CD -_: β_NN 8_CD ,_, and_CC α_NN 5_CD -_: C_NNP )_) domains_NNS joined_VBN
          by_IN a_DT bridging_VBG sheet_NN (_( β_NN 2_CD ,_, β_NN 3_CD ,_, β_NN 20_CD ,_, and_CC β_NN 21_CD )_) [_NN 44_CD ]_NN ._. As_IN
          indicated_VBN by_IN Kwong_NNP 
          et_CC al_NN ._. ,_, all_DT three_CD domains_NNS include_VBP
          variable_JJ regions_NNS ;_: as_IN QUASI_NNP shows_NNS ,_, diversity_NN in_IN all_DT three_CD
          regions_NNS is_VBZ positively_RB selected_VBN (_( Fig_NNP ._. 3_LS )_) ._. The_DT selective_JJ
          advantage_NN we_PRP find_VBP rendered_VBN by_IN diversity_NN in_IN some_DT of_IN these_DT
          regions_NNS (_( 
          e_SYM ._. g_SYM ._. ,_, the_DT "_'' silent_JJ face_NN "_'' )_) has_VBZ been_VBN
          attributed_VBN to_TO neutral_JJ drift_NN [_NN 44_CD ,_, 45_CD ]_NN ,_, thus_RB QUASI_NNP 's_POS
          results_NNS run_VBP counter_RB to_TO previous_JJ interpretations_NNS ._. That_DT is_VBZ ,_,
          QUASI_NNP finds_VBZ that_DT diversity_NN in_IN regions_NNS proposed_VBN to_TO be_VB
          inaccessible_JJ to_TO the_DT immune_JJ system_NN nevertheless_RB confers_VBZ
          selective_JJ advantage_NN on_IN HIV_NNP ._. QUASI_NNP 's_POS findings_NNS may_MD be_VB
          consistent_JJ with_IN the_DT existence_NN of_IN gaps_NNS in_IN the_DT carbohydrate_NN
          groups_NNS thought_VBD to_TO mask_NN the_DT silent_JJ face_NN from_IN gp_NN 120_CD from_IN
          immune_JJ surveillance_NN ._. Interestingly_RB ,_, in_IN
          carbohydrate-building_JJ models_NNS of_IN gp_NN 120_CD ,_, these_DT gaps_NNS
          correspond_VB to_TO codons_NNS where_WRB we_PRP find_VBP variation_NN is_VBZ
          positively_RB selected_VBN (_( P_NN ._. Kwong_NNP ,_, pers_NNS ._. commun_NN ._. )_) ._.
          A_DT "_'' non-neutralizing_JJ "_'' face_NN has_VBZ been_VBN identified_VBN where_WRB
          binding_JJ Abs_NNP generally_RB do_VBP not_RB neutralize_NN HIV_NNP when_WRB gp_NN 120_CD is_VBZ
          oligomerized_JJ [_NN 45_CD ,_, 47_CD ]_NN ;_: these_DT data_NNS were_VBD interpreted_VBN as_IN
          indicating_VBG that_IN the_DT non-neutralizing_JJ face_NN is_VBZ occluded_JJ in_IN
          the_DT trimer_NN and_CC that_IN binding_JJ Abs_NNP are_VBP raised_VBN against_IN shed_VB
          gp_NN 120_CD monomers_NNS ._. However_RB ,_, QUASI_NNP finds_VBZ numerous_JJ positively_RB
          selected_VBN variants_NNS on_IN the_DT non-neutralizing_JJ face_NN of_IN the_DT
          inner_JJ domain_NN ._. Assuming_VBG the_DT "_'' non-neutralizing_JJ "_'' appellation_NN
          is_VBZ appropriate_JJ ,_, how_WRB do_VBP mutations_NNS on_IN this_DT face_NN provide_VB
          selective_JJ advantage_NN to_TO the_DT virus_NN ?_. The_DT obvious_JJ answer_NN is_VBZ
          that_IN mutations_NNS provide_VBP escape_VB not_RB from_IN direct_JJ B-_NNP cell_NN
          immunity_NN but_CC from_IN other_JJ levels_NNS of_IN immunity_NN ,_, such_JJ as_IN
          T-_NNP cell_NN immunity_NN [_NN including_VBG major_JJ histocompatibility_NN
          complex_JJ (_( MHC_NNP )_) presentation_NN ]_NN or_CC indirect_JJ Ab_NNP immunity_NN via_IN
          Ab-dependent_NNP cellular_JJ cytotoxicity_NN (_( where_WRB gp_NN 120_CD molecules_NNS
          found_VBD on_IN infected_JJ cell_NN surfaces_VBZ are_VBP monomers_NNS )_) ._.
          To_TO determine_VB if_IN HIV-_NNP 1_CD viral_JJ sequences_NNS retain_VBP evidence_NN
          that_IN T-_NNP cell_NN immunity_NN is_VBZ a_DT significant_JJ selective_JJ force_NN
          affecting_VBG HIV_NNP quasispeciation_NN ,_, we_PRP used_VBD QUASI_NNP to_TO generate_VB
          a_DT selection_NN map_NN of_IN HIV-_NNP 1_CD RT_NNP (_( Fig_NNP ._. 4_LS )_) ._. Because_IN RT_NNP is_VBZ not_RB a_DT
          surface-expressed_JJ protein_NN ,_, it_PRP is_VBZ not_RB plausible_JJ that_IN the_DT
          positively_RB selected_VBN variants_NNS of_IN RT_NNP have_VBP been_VBN selected_VBN by_IN
          direct_JJ B-_NNP cell_NN immunity_NN ._. 
          A_DT priori_FW ,_, RT_NNP quasispeciation_NN could_MD
          have_VB been_VBN the_DT result_NN of_IN neutral_JJ drift_NN ,_, but_CC because_IN QUASI_NNP
          finds_VBZ that_IN replacement_NN mutations_NNS confer_VBP selective_JJ
          advantage_NN on_IN the_DT virus_NN ,_, we_PRP reject_VBP the_DT neutral_JJ drift_NN
          hypothesis_NNS at_IN the_DT 22_CD RT_NNP codons_NNS ._. If_IN T-_NNP cell_NN immunity_NN
          (_( including_VBG MHC_NNP presentation_NN )_) is_VBZ a_DT selective_JJ pressure_NN
          shaping_VBG RT_NNP quasispeciation_NN ,_, positively_RB selected_VBN variants_NNS
          should_MD be_VB associated_VBN with_IN T-_NNP cell_NN epitopes_NNS ._. When_WRB known_VBN
          T-_NNP cell_NN epitopes_NNS [_NN 48_CD ]_NN are_VBP plotted_VBD on_IN the_DT RT_NNP selection_NN
          map_NN ,_, the_DT positively_RB selected_VBN variants_NNS are_VBP found_VBN to_TO
          localize_NN significantly_RB (_( Fisher_NNP 's_POS exact_JJ test_NN )_) both_DT with_IN
          helper_NN T-_NNP cell_NN epitopes_NNS (_( p_NN =_SYM 3_CD ._. 27_CD ×_NN 10_CD -_: 2_LS )_) and_CC CTL_NNP
          epitopes_NNS (_( p_NN =_SYM 6_CD ._. 58_CD ×_NN 10_CD -_: 3_LS )_) ._. We_PRP conclude_VBP that_IN T-_NNP cell_NN
          immunity_NN is_VBZ a_DT significant_JJ selection_NN pressure_NN shaping_VBG the_DT
          quasispeciation_NN of_IN RT_NNP and_CC presumably_RB is_VBZ a_DT significant_JJ
          factor_NN in_IN the_DT quasispeciation_NN of_IN other_JJ HIV_NNP proteins_NNS ._.
          Thus_RB ,_, because_IN positively_RB selected_VBN gp_NN 120_CD variants_NNS found_VBD
          throughout_IN gp_NN 120_CD may_MD be_VB selected_VBN by_IN T-_NNP cell_NN immunity_NN ,_,
          QUASI_NNP 's_POS finding_NN that_IN the_DT non-neutralizing_JJ face_NN includes_VBZ
          positively_RB selected_VBN variants_NNS is_VBZ not_RB at_IN odds_NNS with_IN models_NNS
          where_WRB the_DT non-neutralizing_JJ face_NN forms_VBZ the_DT gp_NN 120_CD trimer_NN
          interface_NN ._. Nor_CC are_VBP QUASI_NNP 's_POS results_NNS incompatible_JJ with_IN the_DT
          silent_JJ face_NN being_VBG silent_JJ to_TO B-_NNP cell_NN immunity_NN ._. QUASI_NNP 's_POS
          finding_NN that_IN positively_RB selected_VBN variants_NNS may_MD be_VB buried_VBN
          in_IN the_DT gp_NN 120_CD monomer_NN is_VBZ consistent_JJ with_IN escape_NN from_IN
          T-_NNP cell_NN immunity_NN ._.
          In_IN addition_NN to_TO the_DT selection_NN pressure_NN exerted_VBN by_IN
          T-_NNP cell_NN immunity_NN ,_, 3_CD '_POS -_: azido-_NN 3_CD '_POS -_: deoxythymidine_NN (_( AZT_NNP )_) may_MD
          also_RB have_VB provided_VBN selection_NN pressure_NN for_IN RT_NNP
          quasispeciation_NN in_IN the_DT sequences_NNS selection_NN mapped_VBN by_IN
          QUASI_NNP [_NN 59_CD ,_, 51_CD ]_NN ._. Indeed_RB ,_, QUASI_NNP identifies_VBZ six_CD of_IN the_DT
          eight_CD mutations_NNS known_VBN to_TO be_VB associated_VBN with_IN AZT_NNP
          resistance_NN [_NN 52_CD ]_NN as_RB positively_RB selected_VBN (_( N_NNP 67_CD ,_, R_NN 70_CD ,_, W_NNP 210_CD ,_,
          Y_NNP 215_CD ,_, and_CC F_NN 215_CD )_) or_CC possibly_RB positively_RB selected_VBN (_( L_NNP 41_CD )_) to_TO
          HIV-_NNP 1_CD (_( Fig_NNP ._. 4_LS )_) ._. The_DT exceptions_NNS ,_, two_CD mutations_NNS of_IN codon_NN
          219_CD ,_, are_VBP informative_JJ ._. Whereas_IN mutations_NNS at_IN other_JJ codons_NNS
          are_VBP necessary_JJ for_IN high_JJ resistance_NN to_TO AZT_NNP ,_, mutations_NNS at_IN
          codon_NN 219_CD are_VBP not_RB ,_, and_CC codon_NN 219_CD mutations_NNS arise_VBP late_RB in_IN
          infection_NN after_IN earlier_JJR mutations_NNS have_VBP already_RB rendered_VBN
          RT_NNP resistant_JJ to_TO AZT_NNP [_NN 53_CD ]_NN ._. We_PRP conclude_VBP that_IN the_DT
          additional_JJ AZT_NNP resistance_NN conferred_VBD by_IN codon_NN 219_CD
          mutations_NNS did_VBD not_RB provide_VB significant_JJ selective_JJ advantage_NN
          to_TO the_DT profiled_VBN HIV_NNP viruses_NNS ,_, possibly_RB because_IN HIV_NNP had_VBD
          already_RB acquired_VBN the_DT maximum_NN effective_JJ AZT_NNP resistance_NN
          selectable_JJ ,_, 
          in_IN vivo_NN ,_, when_WRB mutations_NNS arose_VBD at_IN
          this_DT codon_NN ._. Alternatively_RB ,_, the_DT lysine_NN at_IN codon_NN 219_CD may_MD be_VB
          important_JJ for_IN proper_JJ 
          in_IN vivo_NN RT_NNP function_NN such_JJ that_IN the_DT
          advantage_NN conferred_VBD by_IN increased_VBN AZT_NNP resistance_NN does_VBZ not_RB
          adequately_RB compensate_VB for_IN impaired_VBN RT_NNP function_NN ._. The_DT RT_NNP
          sequences_NNS we_PRP analyze_VBP were_VBD taken_VBN from_IN patients_NNS who_WP either_CC
          had_VBD no_DT anti-_NN RT_NNP treatment_NN or_CC were_VBD treated_VBN mainly_RB with_IN AZT_NNP
          (_( though_IN some_DT patients_NNS who_WP were_VBD treated_VBN with_IN AZT_NNP were_VBD also_RB
          treated_VBN with_IN 2_CD '_POS ,_, 3_CD '_POS -_: dideoxyinosine_NN )_) [_NN 49_CD ,_, 50_CD ,_, 51_CD ]_NN ._.
          Therefore_RB ,_, we_PRP would_MD predict_VB that_IN mutations_NNS associated_VBN
          with_IN resistance_NN to_TO other_JJ anti-_NN RT_NNP drugs_NNS should_MD not_RB be_VB
          positively_RB selected_VBN in_IN the_DT sequences_NNS QUASI_NNP analyzed_VBD ._. As_IN
          predicted_VBD ,_, QUASI_NNP identifies_VBZ none_NN of_IN the_DT 50_CD RT_NNP mutation_NN
          associated_VBN with_IN resistance_NN to_TO other_JJ drugs_NNS as_RB positively_RB
          selected_VBN (_( compare_VB Figure_NN 4_CD to_TO the_DT Los_NNP Alamos_NNP database_NN [_NN
          52_CD ]_NN )_) ._.
        
      
      
        Conclusion_NNP
        We_PRP have_VBP developed_VBN an_DT algorithm_NN for_IN using_VBG sequence_NN data_NNS
        to_TO map_VB the_DT positively_RB selected_VBN mutations_NNS of_IN viral_JJ
        quasispecies_NNS ._. We_PRP have_VBP used_VBN this_DT method_NN to_TO map_VB the_DT
        positively_RB selected_VBN variants_NNS of_IN influenza_NN A_DT HA_NNP ,_, HIV-_NNP 1_CD RT_NNP ,_,
        and_CC HIV-_NNP 1_CD gp_NN 120_CD ._. Other_JJ obvious_JJ targets_NNS for_IN selection_NN
        mapping_NN are_VBP the_DT hepatitis_NNP C_NNP and_CC foot-and-mouth_JJ disease_NN
        viruses_NNS ._. We_PRP believe_VBP that_IN potentially_RB the_DT most_RBS illuminating_JJ
        use_NN of_IN selection_NN mapping_NN may_MD be_VB the_DT comparison_NN of_IN viral_JJ
        subpopulations_NNS to_TO determine_VB which_WDT variants_NNS are_VBP advantageous_JJ
        under_IN different_JJ selective_JJ pressures_NNS ._. For_IN example_NN ,_, selection_NN
        mapping_NN of_IN HIV_NNP isolates_VBZ with_IN different_JJ cellular_JJ tropisms_NNS
        will_MD allow_VB the_DT determination_NN of_IN mutations_NNS that_WDT are_VBP
        positively_RB selected_VBN depending_VBG on_IN the_DT host_NN cell_NN type_NN ._. Also_RB ,_,
        we_PRP may_MD use_VB selection_NN mapping_NN to_TO analyze_VB HIV_NNP breakthrough_NN
        infections_NNS to_TO determine_VB if_IN vaccines_NNS prevented_VBD the_DT HIV_NNP
        quasispecies_NNS from_IN inhabiting_VBG normally_RB advantageous_JJ regions_NNS
        of_IN the_DT quasispecies_NNS sequence_NN space_NN ._. Finally_RB ,_, we_PRP propose_VBP
        that_IN the_DT positively_RB selected_VBN viral_JJ variants_NNS (_( as_IN opposed_VBN to_TO
        all_DT viral_JJ variants_NNS )_) should_MD be_VB included_VBN in_IN future_JJ ,_, highly_RB
        multivalent_NN vaccines_NNS designed_VBN to_TO compensate_VB for_IN
        B-_NNP cell-selected_JJ antigenic_JJ drift_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          QUASI--the_NNP selection_NN mapping_NN algorithm_NN
          An_DT executable_JJ version_NN of_IN the_DT QUASI_NNP software_NN is_VBZ
          attached_VBN as_IN an_DT additional_JJ file_NN (_( see_VB additional_JJ file_NN 1_LS )_) ._.
          Also_RB attached_VBN are_VBP a_DT users_NNS '_POS manual_JJ (_( user_NN ._. txt_NN -_: see_VB
          additional_JJ file_NN 2_LS )_) and_CC a_DT FASTA_NNP to_TO QUASI_NNP file_VB converter_NN
          PERL_NNP script_NN (_( F_NN 2_CD Q_NNP ._. pl_NN -_: additional_JJ file_NN 3_LS )_) ._. Current_JJ
          versions_NNS of_IN QUASI_NNP are_VBP available_JJ from_IN the_DT authors_NNS or_CC may_MD
          be_VB accessed_JJ at_IN the_DT Los_NNP Alamos_NNP Influenza_NNP Sequence_NNP Database_NNP
          (_( http_NN :_: /_NN /_NN www_NN ._. flu_NN ._. lanl_NN ._. gov_NN /_NN )_) ._.
          For_IN a_DT set_NN of_IN viral_JJ nucleotide_NN sequences_NNS ,_, we_PRP determine_VBP
          the_DT variants_NNS that_WDT confer_VBP selective_JJ advantage_NN by_IN measuring_VBG
          the_DT empirical_JJ replacement_NN to_TO silent_JJ mutation_NN ratio_NN (_( R_NN :_: S_NNP )_)
          of_IN each_DT possible_JJ amino_JJ acid_NN replacement_NN and_CC then_RB
          comparing_VBG this_DT observed_VBN ratio_NN to_TO that_DT which_WDT would_MD be_VB
          expected_VBN if_IN mutation_NN were_VBD unselected_JJ ._. An_DT R_NN :_: S_NNP that_WDT is_VBZ
          found_VBN to_TO be_VB higher_JJR than_IN expected_VBN indicates_VBZ that_IN the_DT
          replacement_NN mutation_NN tested_VBN is_VBZ positively_RB selected_VBN ,_, while_IN
          a_DT lower-than-expected_JJ observed_JJ R_NN :_: S_NNP indicates_VBZ that_IN the_DT
          tested_VBN replacement_NN mutation_NN is_VBZ negatively_RB selected_VBN ._.
          Testing_NNP for_IN an_DT overabundance_NN of_IN replacements_NNS across_IN a_DT
          protein_NN as_IN a_DT whole_NN is_VBZ a_DT reasonable_JJ approach_NN when_WRB only_RB a_DT
          few_JJ nucleotide_NN sequences_NNS are_VBP available_JJ ,_, but_CC because_IN a_DT
          large_JJ number_NN of_IN mutated_VBN viral_JJ sequences_NNS are_VBP currently_RB
          available_JJ ,_, such_JJ aggregation_NN is_VBZ unnecessarily_RB crude_NN ._.
          Better_NNP are_VBP approaches_NNS that_WDT test_NN for_IN an_DT overabundance_NN of_IN
          replacement_NN mutations_NNS at_IN individual_JJ codons_NNS [_NN 23_CD ,_, 36_CD ,_, 37_CD ,_,
          38_CD ]_NN ._. However_RB ,_, these_DT methods_NNS lump_NN together_RB replacement_NN
          mutations_NNS and_CC thus_RB allow_VB negatively_RB selected_VBN mutations_NNS to_TO
          conceal_VB positively_RB selected_VBN mutations_NNS and_CC 
          vice_NN versa_RB (_( 
          e_SYM ._. g_SYM ._. ,_, replacement_NN mutations_NNS at_IN a_DT
          codon_NN may_MD be_VB negatively_RB selected_VBN as_IN a_DT group_NN despite_IN the_DT
          fact_NN that_IN one_CD or_CC more_RBR particular_JJ replacement_NN mutations_NNS
          are_VBP positively_RB selected_VBN )_) ._.
          To_TO overcome_VB these_DT limitations_NNS ,_, the_DT QUASI_NNP algorithm_NN
          does_VBZ not_RB test_VB the_DT overall_JJ R_NN :_: S_NNP of_IN the_DT entire_JJ protein_NN as_IN an_DT
          aggregate_NN ,_, nor_CC does_VBZ QUASI_NNP test_NN the_DT R_NN :_: S_NNP of_IN a_DT codon_NN to_TO all_DT
          its_PRP$ replacement_NN mutations_NNS taken_VBN as_IN a_DT whole_NN ._. Rather_RB ,_, QUASI_NNP
          tests_VBZ the_DT R_NN :_: S_NNP of_IN each_DT particular_JJ replacement_NN mutation_NN at_IN
          each_DT codon_NN ._. That_DT is_VBZ ,_, QUASI_NNP measures_VBZ the_DT R_NN :_: S_NNP of_IN the_DT
          mutations_NNS from_IN a_DT consensus_NN codon_NN towards_IN each_DT individual_JJ
          replacement_NN amino_JJ ._. For_IN example_NN ,_, if_IN the_DT consensus_NN codon_NN at_IN
          a_DT protein_NN position_NN were_VBD ttt_NN (_( Phe_NNP )_) ,_, QUASI_NNP would_MD test_VB the_DT
          R_NN :_: Ss_NNP of_IN all_DT point_NN mutations_NNS from_IN ttt_NN ._. One_CD of_IN these_DT
          mutations_NNS is_VBZ ttt_NN →_NN tat_NN (_( Tyr_NNP )_) ._. QUASI_NNP calculates_VBZ the_DT expected_VBN
          R_NN :_: S_NNP for_IN ttt_NN →_NN tat_NN under_IN the_DT null_NN hypothesis_NNS of_IN neutral_JJ
          drift_NN ._. The_DT expected_VBN S_NNP is_VBZ one_CD because_IN only_RB one_CD mutation_NN
          (_( ttc_NN )_) is_VBZ silent_JJ ,_, and_CC the_DT expected_VBN R_NN is_VBZ also_RB one_CD because_IN
          only_RB one_CD point_NN mutation_NN of_IN ttt_NN (_( tat_NN )_) codes_NNS for_IN Tyr_NNP ,_, so_IN
          the_DT expected_VBN R_NN :_: S_NNP is_VBZ one_CD ,_, in_IN this_DT case_NN ._. If_IN QUASI_NNP rejects_VBZ
          the_DT (_( Jukes-_NNP Cantor_NNP )_) neutral_JJ drift_NN null_NN hypothesis_NNS because_IN
          the_DT observed_VBN R_NN :_: S_NNP is_VBZ significantly_RB higher_JJR than_IN one_CD ,_, then_RB
          QUASI_NNP classifies_VBZ this_DT replacement_NN mutation_NN (_( Tyr_NNP )_) as_RB
          positively_RB selected_VBN ._. Conversely_RB ,_, if_IN QUASI_NNP rejects_VBZ the_DT
          null_NN hypothesis_NNS because_IN the_DT observed_VBN R_NN :_: S_NNP is_VBZ significantly_RB
          lower_JJR than_IN one_CD ,_, then_RB QUASI_NNP determines_VBZ that_IN this_DT
          replacement_NN mutation_NN is_VBZ negatively_RB selected_VBN ._. QUASI_NNP
          performs_VBZ this_DT procedure_NN for_IN all_DT replacement_NN point_NN
          mutations_NNS [_NN 
          e_SYM ._. g_SYM ._. ,_, in_IN the_DT example_NN case_NN ,_, Tyr_NNP
          (_( tat_NN )_) ,_, Ile_NNP (_( att_NN )_) ,_, Leu_NNP (_( tta_NN ,_, ttg_NN ,_, and_CC ctt_NN )_) ,_, Val_NNP (_( gtt_NN )_) ,_, Ser_NNP
          (_( tct_NN )_) ,_, and_CC Cys_NNP (_( tgt_NN )_) ]_NN ._.
          In_IN this_DT paper_NN ,_, selection_NN mapping_NN is_VBZ carried_VBN out_IN
          independent_JJ of_IN the_DT underlying_VBG phylogeny_NN ._. QUASI_NNP uses_VBZ R_NN :_: S_NNP
          to_TO reject_VB the_DT null_NN hypothesis_NNS that_IN the_DT mutational_NN space_NN
          surrounding_VBG the_DT consensus_NN codon_NN is_VBZ distributed_VBN randomly_RB
          among_IN all_DT nine_CD possible_JJ R_NN or_CC S_NNP point_NN mutations_NNS (_( except_IN
          stop_NN codons_NNS ,_, which_WDT are_VBP considered_VBN to_TO be_VB disallowed_VBD )_) ._. This_DT
          allows_VBZ R_NN :_: S_NNP calculations_NNS to_TO be_VB applied_VBN to_TO viral_JJ sequences_NNS
          whose_WP$ ancestral_JJ sequence_NN is_VBZ unclear_JJ or_CC unknown_JJ ._. This_DT is_VBZ a_DT
          both_DT an_DT advantage_NN and_CC a_DT disadvantage_NN over_IN analyses_NNS that_WDT
          rely_VBP on_IN phylogeny_NN ._. Phylogeny_NNP is_VBZ difficult_JJ to_TO determine_VB
          accurately_RB and_CC uniquely_RB ,_, and_CC relying_VBG on_IN phylogeny_NN ignores_VBZ
          the_DT persistence_NN of_IN positively_RB selected_VBN replacement_NN
          mutations_NNS (_( the_DT major_NN effect_NN of_IN selection_NN )_) ._. On_IN a_DT practical_JJ
          level_NN ,_, using_VBG phylogeny_NN to_TO reconstruct_VB viruses_NNS '_POS mutational_NN
          histories_NNS and_CC then_RB using_VBG intuited_JJ mutations_NNS leaves_VBZ one_CD
          with_IN insufficient_JJ data_NNS to_TO determine_VB positively-selected_JJ
          codons_NNS [_NN 36_CD ]_NN unless_IN ,_, as_IN some_DT have_VBP done_VBN ,_, one_CD assumes_VBZ
          observed_VBN drift_VB is_VBZ neutral_JJ and_CC then_RB tests_VBZ for_IN codons_NNS where_WRB
          selection_NN is_VBZ more_RBR positive_JJ than_IN average_JJ [_NN 23_CD ,_, 38_CD ]_NN ._. The_DT
          significance_NN problem_NN can_MD be_VB compounded_VBN when_WRB one_CD is_VBZ
          looking_VBG for_IN independent_JJ occurrences_NNS of_IN particular_JJ
          mutations_NNS ;_: often_RB ,_, there_EX simply_RB has_VBZ not_RB been_VBN enough_JJ
          sequence_NN evolution_NN in_IN HIV_NNP or_CC influenza_NN to_TO map_VB positively_RB
          selected_VBD variants_NNS if_IN the_DT retention_NN of_IN positively_RB selected_VBN
          mutations_NNS is_VBZ ignored_VBN ._. The_DT drawback_NN of_IN ignoring_VBG phylogeny_NN
          is_VBZ a_DT potentially_RB high_JJ false_JJ positive_JJ rate_NN (_( see_VB
          below_IN )_) ._.
          Empirical_NNP R_NNP :_: S_NNP is_VBZ compared_VBN to_TO neutral_JJ R_NN :_: S_NNP by_IN means_NNS of_IN a_DT
          two-sided_JJ test_NN of_IN the_DT binomial_NN distribution_NN ._. For_IN each_DT
          codon_NN ,_, we_PRP test_VBP the_DT null_NN hypothesis_NNS that_IN all_DT nine_CD point_NN
          mutants_NNS are_VBP equally_RB probable_JJ ._. The_DT quotient_NN 
          p_NN =_SYM R_NN /_NN (_( R_NN +_NN S_NNP )_) is_VBZ the_DT probability_NN of_IN a_DT
          replacement_NN mutation_NN at_IN this_DT codon_NN if_IN each_DT nucleotide_NN is_VBZ
          equally_RB mutable_JJ and_CC each_DT of_IN the_DT three_CD mutational_NN targets_NNS
          at_IN that_DT codon_NN are_VBP equally_RB likely_JJ ._. The_DT numerator_NN ,_, R_NN ,_, is_VBZ
          the_DT number_NN of_IN point_NN mutations_NNS that_WDT lead_VBP from_IN the_DT
          consensus_NN codon_NN to_TO the_DT target_NN amino_JJ acid_NN ._. The_DT chance_NN of_IN
          observing_VBG 
          r_LS replacement_NN mutations_NNS is_VBZ given_VBN by_IN
          the_DT binomial_NN distribution_NN ,_, ,_, where_WRB 
          n_NN is_VBZ the_DT number_NN of_IN codons_NNS providing_VBG
          data_NNS for_IN this_DT position_NN ._. To_TO form_VB a_DT two-sided_JJ test_NN ,_, we_PRP sum_NN
          all_DT terms_NNS 
          b_SYM (_( 
          kn_NN ,_, ,_, 
          p_NN )_) such_JJ that_IN 
          b_SYM (_( 
          kn_NN ,_, ,_, 
          p_NN )_) is_VBZ not_RB greater_JJR than_IN 
          b_SYM (_( 
          rn_NN ,_, 
          p_NN ,_, )_) ,_, where_WRB 
          k_NN is_VBZ in_IN the_DT set_VBN (_( 0_CD ,_, ._. ._. ._. ,_, 
          n_NN )_) and_CC 
          r_LS is_VBZ the_DT number_NN of_IN observed_JJ
          replacement_NN mutations_NNS ._. In_IN other_JJ words_NNS ,_, we_PRP sum_NN the_DT chances_NNS
          of_IN all_DT events_NNS that_WDT are_VBP no_DT more_RBR likely_JJ than_IN that_DT of_IN the_DT
          observation_NN ._. If_IN this_DT sum_NN ,_, α_NN ,_, is_VBZ small_JJ (_( 
          e_SYM ._. g_SYM ._. ,_, not_RB greater_JJR than_IN 0_CD ._. 05_CD )_) ,_, we_PRP
          reject_VBP the_DT null_NN hypothesis_NNS at_IN the_DT α_NN level_NN of_IN
          significance_NN ._.
        
        
          Working_JJ example_NN
          We_PRP analyze_VBP the_DT following_VBG scenario_NN as_IN a_DT working_VBG example_NN
          (_( Table_NNP 1_LS )_) ._.
          Additional_JJ file_NN 1_CD
          Click_NNP here_RB for_IN file_NN
          Additional_JJ file_NN 2_CD
          Click_NNP here_RB for_IN file_NN
          Additional_JJ file_NN 3_CD
          Click_NNP here_RB for_IN file_NN
          The_DT consensus_NN codon_NN is_VBZ given_VBN as_IN ttt_NN (_( Phe_NNP ;_: Table_NNP 1_CD ,_,
          column_NN 1_LS )_) ._. Each_DT observed_VBN mutation_NN is_VBZ also_RB given_VBN (_( Table_NNP 1_CD ,_,
          columns_NNS 1_CD -_: 3_LS )_)
          Because_IN we_PRP know_VBP the_DT frequency_NN of_IN silent_JJ mutations_NNS
          (_( given_VBN as_IN 10_CD in_IN this_DT example_NN ;_: Table_NNP 1_CD ,_, column_NN 3_LS )_) ,_, we_PRP also_RB
          know_VBP the_DT expected_VBN R_NN :_: S_NNP for_IN each_DT replacement_NN mutation_NN
          (_( Table_NNP 1_CD ,_, column_NN 4_LS )_) ._. That_DT is_VBZ ,_, if_IN selection_NN is_VBZ neutral_JJ for_IN
          any_DT particular_JJ replacement_NN mutation_NN ,_, we_PRP can_MD calculate_VB the_DT
          incidence_NN of_IN each_DT replacement_NN mutation_NN we_PRP expect_VBP to_TO
          observe_VB (_( by_IN looking_VBG at_IN a_DT table_NN of_IN the_DT genetic_JJ code_NN )_) ._.
          Using_VBG the_DT given_VBN frequency_NN of_IN each_DT mutation_NN observed_VBD ,_,
          we_PRP also_RB know_VBP what_WP the_DT observed_VBN R_NN :_: S_NNP is_VBZ in_IN each_DT case_NN (_( Table_NNP
          1_CD ,_, column_NN 5_LS )_) ._.
          Now_RB we_PRP use_VBP a_DT two-tailed_JJ test_NN of_IN the_DT binomial_NN
          distribution_NN to_TO determine_VB if_IN each_DT observed_VBN R_NN :_: S_NNP is_VBZ
          significantly_RB different_JJ from_IN the_DT corresponding_JJ expected_VBN
          R_NN :_: S_NNP (_( Table_NNP 1_CD ,_, column_NN 6_CD )_) ._. In_IN some_DT cases_NNS ,_, the_DT differences_NNS
          are_VBP significant_JJ ,_, in_IN which_WDT case_NN the_DT appropriate_JJ
          replacement_NN mutation_NN is_VBZ assigned_VBN positive_JJ or_CC negative_JJ
          selection_NN (_( positive_JJ if_IN the_DT observed_VBN R_NN :_: S_NNP is_VBZ larger_JJR than_IN
          expected_VBN and_CC negative_JJ if_IN the_DT observed_VBN R_NN :_: S_NNP is_VBZ lower_JJR than_IN
          expected_VBN )_) ._. Otherwise_RB ,_, the_DT selection_NN is_VBZ assigned_VBN to_TO be_VB
          neutral_JJ drift_NN ._.
          The_DT QUASI_NNP algorithm_NN thus_RB indicates_VBZ at_IN this_DT exemplary_JJ
          codon_NN that_IN both_DT tyrosine_NN and_CC serine_NN are_VBP positively_RB
          selected_VBN ;_: isoleucine_NN ,_, leucine_NN ,_, and_CC cystine_NN are_VBP negatively_RB
          selected_VBN ;_: and_CC the_DT selective_JJ advantage_NN or_CC disadvantage_NN of_IN
          valine_NN is_VBZ indistinguishable_JJ from_IN neutral_JJ drift_NN ._. Any_DT other_JJ
          ttt_NN codon_NN will_MD have_VB its_PRP$ own_JJ selective_JJ pressures_NNS assessed_VBN
          in_IN a_DT similar_JJ but_CC independent_JJ testing_NN procedure_NN ._.
        
        
          Minimum_NNP sequences_NNS
          For_IN each_DT possible_JJ replacement_NN mutation_NN ,_, a_DT minimum_JJ
          number_NN of_IN mutations_NNS will_MD need_VB to_TO be_VB observed_VBN for_IN a_DT
          selective_JJ event_NN to_TO be_VB detected_VBN ._. This_DT minimum_JJ number_NN
          differs_VBZ depending_VBG on_IN the_DT consensus_NN codon_NN and_CC the_DT level_NN of_IN
          significance_NN ._. We_PRP have_VBP calculated_VBN the_DT minimum_JJ number_NN of_IN
          mutations_NNS needed_VBN to_TO achieve_VB the_DT 5_CD %_NN significance_NN level_NN ._. At_IN
          the_DT lower_JJR bound_JJ of_IN this_DT range_NN ,_, only_RB 2_CD replacement_NN
          mutations_NNS will_MD be_VB required_VBN to_TO detect_VB positive_JJ selection_NN
          for_IN any_DT replacement_NN mutation_NN from_IN cta_NN or_CC ctg_NN ._. Any_DT
          replacement_NN mutation_NN from_IN cta_NN or_CC ctg_NN has_VBZ an_DT expected_VBN R_NN :_: S_NNP
          of_IN 1_CD :_: 4_CD ,_, and_CC thus_RB an_DT observed_VBN R_NN :_: S_NNP of_IN 2_CD :_: 0_CD will_MD be_VB
          sufficient_JJ to_TO reject_VB neutral_JJ drift_NN in_IN favor_NN of_IN positive_JJ
          selection_NN ._. Conversely_RB ,_, detecting_VBG negative_JJ selection_NN at_IN a_DT
          cta_NN or_CC ctg_NN codon_NN is_VBZ difficult_JJ ._. At_IN the_DT upper_JJ bound_VBN of_IN the_DT
          range_NN ,_, a_DT minimum_NN of_IN 17_CD observed_VBD mutations_NNS are_VBP required_VBN to_TO
          detect_VB negative_JJ selection_NN at_IN such_JJ a_DT codon_NN (_( 0_CD :_: 17_CD is_VBZ
          significantly_RB lower_JJR than_IN 1_CD :_: 4_LS )_) ._. For_IN the_DT most-typical_JJ
          codon_NN ,_, the_DT expected_VBN R_NN :_: S_NNP is_VBZ 1_CD :_: 3_CD ._. For_IN these_DT modal_NN codons_NNS ,_,
          at_IN least_JJS 3_CD mutations_NNS must_MD be_VB observed_VBN to_TO detect_VB positive_JJ
          selection_NN (_( 
          i_NNP ._. e_SYM ._. ,_, if_IN observed_JJ R_NN :_: S_NNP =_SYM 3_CD :_: 0_CD )_) ._. At_IN
          the_DT same_JJ most-typical_JJ codon_NN ,_, 12_CD mutations_NNS are_VBP required_VBN ,_,
          at_IN a_DT minimum_NN ,_, to_TO detect_VB negative_JJ selection_NN (_( 
          i_NNP ._. e_SYM ._. ,_, if_IN observed_JJ R_NN :_: S_NNP =_SYM 0_CD :_: 12_CD )_) ._.
          Because_IN identification_NN of_IN positive_JJ selection_NN is_VBZ generally_RB
          the_DT goal_NN ,_, the_DT QUASI_NNP algorithm_NN appears_VBZ to_TO have_VB a_DT practical_JJ
          advantage_NN over_IN extant_NN selection_NN detectors_NNS ,_, which_WDT require_VBP
          either_CC many_JJ more_JJR mutations_NNS or_CC a_DT biased_VBN expectation_NN of_IN
          neutral_JJ drift_NN in_IN order_NN to_TO detect_VB positive_JJ selection_NN ._.
        
        
          False-positive_NNP testing_NN
          False_NNP positives_NNS are_VBP likeliest_NN when_WRB drift_VB is_VBZ completely_RB
          neutral_JJ (_( 
          e_SYM ._. g_SYM ._. ,_, as_IN was_VBD found_VBN by_IN Suzuki_NNP and_CC
          Gojobori_NNP [_NN 36_CD ]_NN )_) ._. One_PRP may_MD estimate_VB the_DT maximum_NN frequency_NN
          of_IN false_JJ positives_NNS by_IN testing_VBG simulated_JJ sequences_NNS
          generated_VBN under_IN neutral_JJ drift_NN parameters_NNS ._. We_PRP used_VBD the_DT
          EVOLVER_NNP program_NN of_IN the_DT PAML_NNP package_NN [_NN 54_CD ]_NN to_TO generate_VB
          sequences_NNS drifting_VBG under_IN neutral_JJ Jukes-_NNP Cantor_NNP evolution_NN ._.
          For_IN each_DT simulation_NN ,_, we_PRP generated_VBD 300_CD related_VBN sequences_NNS
          of_IN length_NN 999_CD and_CC with_IN average_JJ branch_NN lengths_NNS varying_VBG in_IN
          0_CD ._. 1_CD length_NN intervals_NNS from_IN 0_CD ._. 1_CD to_TO 1_CD ._. 0_CD ;_: each_DT parameter_NN set_VBN
          was_VBD used_VBN to_TO generate_VB 10_CD sets_NNS of_IN 300_CD sequences_NNS ._. False_NNP
          positive_JJ percentages_NNS [_NN Fig_NNP ._. 5_LS ;_: false_JJ positive_JJ percentage_NN =_SYM
          false_JJ positives_NNS /_NN (_( false_JJ positives_NNS +_NN neutral_JJ drift_NN
          variants_NNS )_) ]_NN were_VBD extremely_RB low_JJ (_( ∼_NN 2_CD %_NN )_) for_IN relatively_RB long_JJ
          branch_NN lengths_NNS (_( 0_CD ._. 1_LS -_: 1_CD ._. 0_CD )_) ._. Extremely_NNP high_JJ false_JJ positive_JJ
          rates_NNS (_( up_IN to_TO 70_CD %_NN )_) were_VBD found_VBN for_IN extremely_RB short_JJ branch_NN
          lengths_NNS (_( maximum_NN at_IN 0_CD ._. 001_CD )_) ._. As_IN accurate_JJ branch_NN lengths_NNS
          are_VBP calculated_VBN using_VBG maximum_NN likelihood_NN phylogeny_NN ,_, these_DT
          branch_NN lengths_NNS may_MD be_VB used_VBN to_TO find_VB the_DT appropriate_JJ
          false-positive_JJ percentage_NN ._. For_IN instance_NN ,_, if_IN the_DT branch_NN
          length_NN were_VBD 0_CD ._. 01_CD [_NN as_IN appears_VBZ appropriate_JJ for_IN HA_NNP
          (_( unpublished_JJ observation_NN )_) ]_NN ,_, then_RB the_DT maximum_NN false_JJ
          positive_JJ rate_NN would_MD be_VB estimated_VBN at_IN 32_CD %_NN ._. We_PRP then_RB use_VBP the_DT
          calculated_VBN neutral_JJ drift_NN frequency_NN (_( from_IN QUASI_NNP )_) as_IN an_DT
          estimator_NN for_IN the_DT maximum_NN false_JJ positives_NNS ._. If_IN (_( as_IN we_PRP
          report_VBP )_) HA_NNP is_VBZ found_VBN to_TO have_VB 5_CD neutral_JJ drift_NN variants_NNS ,_,
          then_RB we_PRP would_MD expect_VB a_DT maximum_NN of_IN 2_CD ._. 3_CD
          false-positives_JJ ._.
        
        
          Selection_NN mapping_NN
          QUASI_NNP presents_VBZ its_PRP$ results_NNS in_IN the_DT following_JJ
          format_NN :_:
          1_LS ._. The_DT consensus_NN amino_JJ acids_NNS are_VBP written_VBN in_IN capital_NN
          letters_NNS ._.
          2_LS ._. Beneath_IN each_DT consensus_NN amino_JJ acid_NN are_VBP written_VBN in_IN
          capital_NN letters_NNS all_DT variants_NNS determined_VBN to_TO be_VB positively_RB
          selected_VBN (_( in_IN descending_VBG order_NN of_IN frequency_NN )_) ._.
          3_LS ._. The_DT negatively_RB selected_VBN variants_NNS are_VBP not_RB shown_VBN ._.
          4_LS ._. In_IN lowercase_NN letters_NNS and_CC interspersed_VBN according_VBG to_TO
          their_PRP$ frequencies_NNS among_IN the_DT positively_RB selected_VBN variants_NNS
          are_VBP variants_NNS where_WRB the_DT neutral_JJ drift_NN null_NN hypothesis_NNS
          cannot_NN be_VB rejected_VBN with_IN the_DT given_VBN sequence_NN data_NNS ._. As_IN a_DT
          reasonable_JJ but_CC arbitrary_JJ cut-off_JJ ,_, we_PRP include_VBP apparently_RB
          unselected_JJ variants_NNS if_IN they_PRP are_VBP among_IN the_DT 2_CD H_NNP +_NN σmost_NN
          frequent_JJ variants_NNS ,_, where_WRB 
          H_NNP is_VBZ the_DT Shannon_NNP information_NN
          content_NN of_IN the_DT site_NN and_CC σ_NN is_VBZ the_DT standard_JJ error_NN of_IN its_PRP$
          estimation_NN [_NN 55_CD ]_NN ._. is_VBZ the_DT 
          i_NNP th_NN fraction_NN of_IN amino_JJ acids_NNS at_IN the_DT
          site_NN (_( the_DT alignment_NN gap_NN is_VBZ counted_VBN as_IN a_DT 21_CD st_NN amino_JJ acid_NN )_) ._.
          For_IN the_DT Shannon_NNP calculation_NN ,_, alignment_NN gaps_NNS are_VBP
          considered_VBN distinct_JJ from_IN "_'' no_DT data_NNS "_'' gaps_NNS (_( artifacts_NNS of_IN
          indeterminate_JJ sequencing_VBG or_CC sequence_NN fragment_NN overlaps_NNS ;_:
          such_JJ data_NNS absences_NNS are_VBP excluded_VBN from_IN calculation_NN )_) ._.
        
        
          Sequences_NNP
          Nucleotide_NNP sequences_NNS were_VBD downloaded_JJ from_IN GenBank_NNP at_IN
          the_DT NIH_NNP ._. Sequences_NNP were_VBD included_VBN only_RB if_IN they_PRP were_VBD
          isolated_VBN in_IN the_DT field_NN and_CC were_VBD not_RB obviously_RB pseudogenes_NNS
          (_( sequences_NNS containing_VBG premature_JJ stop_NN codons_NNS were_VBD removed_VBN
          from_IN consideration_NN )_) ._. We_PRP analyzed_VBD 310_CD sequences_NNS of_IN
          human-infective_JJ influenza_NN A_DT (_( H_NNP 3_CD serotype_NN )_) ,_, 6_CD ,_, 151_CD HIV-_NNP 1_CD
          gp_NN 120_CD sequences_NNS ,_, and_CC 400_CD HIV-_NNP 1_CD RT_NNP sequences_NNS ._. All_DT
          sequences_NNS were_VBD pre-aligned_JJ with_IN PILEUP_NNP [_NN 56_CD ]_NN and_CC /_NN or_CC
          DIALIGN_NNP 2_CD [_NN 57_CD ]_NN then_RB hand-corrected_JJ ._.
        
      
      
        Abbreviations_NNP
        HIV_NNP ,_, human_JJ immunodeficiency_NN virus_NN ;_: HA_NNP ,_, hemagglutinin_NN ;_:
        Ab_NNP ,_, antibody_NN ;_: gp_NN 120_CD ,_, glycoprotein_NN 120_CD ;_: RT_NNP ,_, reverse_VB
        transcriptase_NN ;_: R_NN :_: S_NNP ,_, replacement_NN to_TO silent_JJ mutation_NN ratio_NN ;_:
        CD_NNP 4_CD BS_NNP ,_, CD_NNP 4_CD binding_JJ site_NN epitope_NN ;_: CD_NNP 4_CD i_NNP ,_, CD_NNP 4_CD -_: induced_VBN epitope_NN ;_:
        MHC_NNP ,_, major_JJ histocompatibility_NN complex_JJ ;_: AZT_NNP ,_,
        3_CD '_POS -_: azido-_NN 3_CD '_POS -_: deoxythymidine_NN ._.
      
    
  
